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Abstract 
Objective: To evaluate aggressiveness during a major depressive episode (MDE) and 
its relationship with bipolar disorder (BD) in a post-hoc analysis of the BRIDGE-II-
MIX study. 
Method: A total of 2,811 individuals were enrolled in this multicenter cross-sectional 
study. MDE patients with (MDE-A, n=399) and without aggressiveness (MDE-N, 
n=2,412) were compared through Chi-square test or Student’s t-test. A stepwise 
backward logistic regression model was performed. 
Results: MDE-A group was more frequently associated with BD (p<0.001) whilst 
aggressiveness was negatively correlated with unipolar depression (p<0.001). At the 
logistic regression aggressiveness was associated with: the age at first depressive 
episode (p<0.001); the severity of mania (p=0.03); the diagnosis of BD (p=0.001); 
comorbid borderline personality disorder (BPD) (p<0.001) but not substance abuse 
(p=0.63); no current psychiatric treatment (p<0.001); psychotic symptoms (p=0.007); 
the marked social/occupational impairment (p=0.002). The variable most significantly 
associated with aggressiveness was the presence of DSM-5 mixed features (p<0.001, 
OR=3.815). After the exclusion of BPD, the variable of lifetime suicide attempts 
became significant (p=0.013, OR=1.405). 
Conclusion: Aggressiveness seems to be significantly associated with bipolar spectrum 
disorders, independently from BPD and substance abuse. Aggressiveness should be 
considered as a diagnostic criterion for the mixed features specifier and a target of 
tailored treatment strategy.  
 
Keys words: aggressiveness, bipolar disorder, DSM-5 mixed features specifier, major 
depressive episode 
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Significant outcomes 
  In this post-hoc analysis of the BRIDGE-II-MIX study, the presence of 
aggressive behaviors was mainly related with socio-demographic and clinical 
characteristics associated with bipolarity. 
  The most relevant clinical variable associated with aggressiveness during a 
major depressive episode was the presence of mixed features. 
  The identification of aggressive behaviors could be the target of a tailored 
treatment strategy in this subgroup of bipolar disorder patients.   
 
Limitations  
  There is a possible bias due to the fact that the psychiatrists involved in the 
study were those with a particular interest in bipolar disorder. 
  This is a post-hoc analysis of the BRIDGE-II-Mix study, whose primary aim 
was not aggressiveness. 
  The retrospective assessment of aggressiveness avoided to explain causality and 
could possibly lead to self-report bias 
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Introduction 
Aggressiveness is defined as an overt behavior involving intent to inflict noxious 
stimulation or to behave destructively towards another organism or object (1). In 
psychiatry, it is a behavioral or motor response associated with intent to do harm and it 
may be self-directed (2).  
 Several psychiatric disorders, including mood disorders, have been associated 
with increased rates of aggressiveness and violent behaviors (3). Particularly, bipolar 
disorder (BD) patients presented increased risk for aggressive behaviors (4,5). Indeed, 
aggressiveness has assumed particular importance as a core feature of manic and mixed 
states (6), independently from psychosis (7), and often emerging as a correlate of 
comorbid substance abuse and suicidality (8). 
 In comparison with subjects with no-BD, but suffering from other psychiatric 
disorders, and healthy controls, BD patients showed in previous studies increased self-
reported verbal and physical aggressiveness, particularly during acute episodes and 
independently from BD subtypes, severity and polarity of the current episode, psychotic 
symptoms and current pharmacological treatments (4,9). In addition, manic patients 
showed the highest odds ratio for aggressive incidents among psychiatric inpatients 
(10). 
 As for trait characteristics of depressive episodes, it has been found that BD-I 
and BD-II depressed patients had more life-time aggressiveness/hostility than unipolar 
depressed patients (11). 
 Previous studies have shown that comorbidity with other disorders, namely 
substance and alcohol abuse and borderline personality disorder (BPD), increased the 
risk of aggressiveness in BD patients (12,13).  
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 Several factor analyses described the clinical context of aggressiveness in mania. 
Aggressiveness was associated with paranoia and irritability, loading on the same factor 
(“irritable aggressiveness”) (14). In another factor analysis, aggressiveness loaded on 
the same factor as irritability, uncooperativeness, impatience and lack of insight, 
suggesting the existence of a distinct subtype of mania defined as “aggressive” (7). In a 
more recent study, the factor analysis revealed 5 factors, and one of them was termed 
‘‘Dysphoria’, with positive significant loading for hostility, uncooperativeness, and 
suspiciousness, representing one of the two classical aspects of manic states (15). In this 
context, aggressiveness could represent a core feature of manic and mixed episodes of 
BD, and might be a persistent trait in the sense of appearing in the same patients across 
repeated episodes.    
 Despite these previous findings, aggressiveness is not currently considered as a 
DSM diagnostic criterion of mania and consequently is not included in the DSM-5 
mixed features in both bipolar and unipolar depressive episodes (16). In fact, only 
irritable mood represents a major defining characteristic of manic episodes since the 
first edition of DSM (17) and across the different revisions of the manual up to the last 
DSM-5. The DSM-5 fails to include the most common symptoms of mixity, including 
anxiety, agitation, and irritability as criteria for mixed features (18,19).  
 Few studies between those mentioned above evaluated possible clinical 
correlates of aggressiveness during a major depressive episode (MDE) across mood 
disorders. These studies were conducted on small samples of patients or derived only 
from one psychiatric center.   
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Aims of the study  
The aim of the present post-hoc analysis was to assess the relationship between BD 
diagnosis or features and the presence of aggressive behaviors during a major 
depressive episode. We explored the possible clinical and treatment implications of this 
association.  
 
Material and methods 
Sample and assessment 
This study is a post-hoc analysis of the BRIDGE-II-Mix study. The general 
methodology of the BRIDGE-II-MIX study was described in detail in previous reports 
(20–23). The BRIDGE-II-Mix study was a multicenter, international, non-
interventional, cross-sectional study. It was conducted between June 2009 and July 
2010 in 239 centers in Bulgaria, Egypt, Morocco, the Netherlands, Portugal, Russia, 
Spain, and Turkey where hospital-based or community psychiatrists were expected to 
enroll consecutively 10-20 eligible adult patients aged 18 or older consulting for a MDE 
according to the Diagnostic and Statistical Manual of Mental Disorders-IV edition 
(DSM-IV) criteria during a three month recruitment period. 
 The selection of the different centers in each country would reflect the 
psychiatric healthcare provision and the patient care typical of the country’s practice 
and regional diversity. Each center collected anonymous screening logs of the patients. 
Reasons for nonparticipation were pre-coded (refusal to participate, patient unable to 
complete the questionnaire, and other). Patients presenting with an acute non-
psychiatric condition/emergency were excluded. 
 From the 239 psychiatrists involved in the study, 237 returned their site 
questionnaire. A total of 2,811 patients agreed to participate and provided complete 
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data, representing the full analysis population. Demographic features were generally 
similar across countries. 
 The study was conducted according to the Declaration of Helsinki (Hong Kong 
Amendment; http://www.wma.net) and the Good Epidemiology Practice and the 
International Epidemiologic Association (IEA) European Federation (http://ieaweb.org). 
Good Epidemiologic Practice (GEP)–IEA Guidelines were followed for proper conduct 
of epidemiologic research, as well as pertinent national, legal and regulatory 
requirements. Written informed consent was obtained from each patient. In each 
country, the protocol was approved by the local ethics committee. 
 
Data collection 
 For each patient, the psychiatrists completed a case report, incorporating 
inclusion criteria, socio-demographic variables (age, gender, marital status), inpatient or 
outpatient status, history of psychiatric symptoms (mood symptoms, postpartum 
depression, suicide attempts), and previous psychiatric hospitalizations. Features of the 
MDE, including bipolar symptoms listed in the DSM-IV-TR (24) diagnostic criteria for 
BD, known risk factors for BD (e.g., family history of BD and postpartum depression), 
previous response to antidepressants, psychiatric comorbidity, current treatment were 
recorded. The functional status was determined by the investigator using the Global 
Assessment of Functioning (GAF) (25) and the global illness severity was assessed 
through the Clinical Global Impression-Bipolar Version (CGI-BP) (26).  
 The evaluation packet was explicitly structured to use skills that fully trained 
psychiatrists would have and routinely apply in conducting an initial evaluation of an 
acutely ill patient. No rating scales requiring calibration with a standard were 
incorporated. Raters were instructed to follow their usual practice, as training might 
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have altered these practices and been seen as a biasing factor.  
The primary objective of the BRIDGE-II-Mix study was to establish the 
frequency of depressive mixed states by analyzing all the relevant symptoms of either 
pole. The frequency of depressive mixed states was post hoc defined as (i) the 
proportion of patients fulfilling the DSM-5 criteria for MDE with mixed features 
(DSM-5-MXS) (16), or (ii) research-based diagnostic criteria for depressive mixed 
states (RBDC-MXS). RBDC-MXS are defined by the presence of MDE plus three of 
the following 14 hypomanic symptoms for at least a week: irritable mood, 
emotional/mood lability, distractibility, psychomotor agitation, impulsivity, aggression 
(verbal or physical), racing thoughts, more talkative/pressure to keep talking, 
hyperactivity, increased energy, risky behavior, grandiosity, elation and hypersexuality. 
The proportion of patients fulfilling the criteria for BD according to the DSM-IV-TR 
and bipolarity specifier proposed by Angst et al. (27,28) was also identified.  
 The objective of the present analysis of the BRIDGE-II-Mix study data was to 
assess the specific features of patients with (MDE-A) or without (MDE-N) 
aggressiveness.  
 An operational clinical definition of aggressiveness has been used, defined by 
the presence of at least one of the following behaviors during the index MDE: 1. 
Physical Aggressiveness (PHY): a. ever threatened or b. hit people, or c. got into fights 
more than most people or d. become so mad to have broken things; 2. Verbal 
Aggressiveness (VER): a. to argue a lot with other people, or b. to can’t help getting 
into arguments when people disagree, or c. to get very angry for no good reason with 
troubles in self-controlling.  
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Statistical analysis 
The Chi-square test was used for comparison between groups for categorical variables 
and Student’s t-test for continuous variables. The bivariate analysis involved many tests 
of statistical significance, raising the problem of type I errors. For this reason, we 
corrected for multiple comparisons and utilized a Bonferroni-corrected threshold for 
statistical significance, including in the logistic regression only those clinically sound 
variables under this threshold of 0.004. A stepwise backward logistic regression model 
was then used to identify the association between aggressiveness and 10 significant 
variables (BD diagnosis, DSM-5-MXS, severity of mania, comorbid BPD, comorbid 
substance abuse, lifetime suicide attempts, psychotic features, marked impairment in 
functioning, no psychiatric treatment, age at first depressive episode). The presence of 
mixed features in this post-hoc analysis was defined according to the DSM-5 mixed 
specifier (DSM-5-MXS). The stepwise modeling procedure started with the full model 
and consisted, for each step, in eliminating the least statistically significant variable 
from the model and re-computing the revised model, until all remaining variables were 
at p<0.1. Odds ratios with 95% confidence intervals were used for observed 
associations. All tolerance values in the regression analyses were > 0.2 and all variance 
inflation factors were < 2, thereby indicating that multicollinearity was not a source of 
bias in the regression models (29). Statistical analyses were performed using the 
Statistical Package for Social Sciences (Statistical Package for Social Science-SPSS, 
23.0 version for Windows Inc., Chicago, IL, USA). All p values were two-tailed and 
statistical significance was set at p<0.05.  
 
Results 
Clinical features: MDE-A patients versus MDE-N patients 
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From a total sample of 2,811 patients, 399 (14.2%) presented verbal or physical 
aggressiveness (MDE-A group) during the index MDE. The socio-demographic and 
clinical features are reported in Table 1. 
 Patients in the MDE-A group were diagnosed more frequently with BD 
(<0.001), in particular BD-I (<0.001) but not BD-II (0.997), than those in the MDE-N 
group (see Table 1). The presence of aggressiveness was negatively associated with the 
diagnosis of unipolar depression (p<0.001). MDE-A group more frequently presented 
DSM-5-MXS than MDE-N group (p<0.001). 
 Patients in the MDE-A group showed higher rates of comorbid disorders 
compared to those in the MDE-N group such as: BPD (p<0.001), anxiety disorder 
(p<0.001), eating disorders (p=0.003) and attention-deficit hyperactivity disorder 
(ADHD) (p=0.011). 
 Patients in the MDE-A reported more frequently a current substance abuse 
(p=0.003) but not a current alcohol abuse (p=0.086) than those in the MDE-N group 
(see Table 1). In both cases the alcohol or substance abuse was not in the context of 
dependence of alcohol (67.2% versus 61%, p=0.022) or substance (66.9% versus 
61.4%, p=0.04) dependence. Patients in the MDE-A group more frequently reported 
recurrent alcohol- (2.8% versus 0.8%, p=0.002) and substance-related (2% versus 0.2%, 
p<0.001) legal problems compared to patients in the MDE-N group.  
 
Functioning and severity of patients in the MDE-A group 
The severity of depression (p=0.044), mania (p<0.001) and overall BD (p<0.001) were 
significantly higher in the MDE-A group compared with the MDE-N group. The GAF 
score was significantly lower in the MDE-A group than in the MDE-N group (p=0.015) 
(see Table 1). 
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 Patients in the MDE-A group presented with more marked impairment in 
social/occupational functioning (49.6% versus 24%, p<0.001) than patients in the 
MDE-N group. 
 The presence of psychotic symptoms was more represented in the MDE-A group 
than in the MDE-N group (15.5% versus 7%, p<0.001).  
  
Lifetime psychiatric history characteristics of patients in the MDE-A group 
Age at first psychiatric symptoms (p<0.001) and age at first depressive episode 
(p<0.001) was significantly lower in patients in the MDE-A group (see Table 1). 
 The total number of mood episodes was significantly higher in patients in the 
MDE-A group (p=0.006). 
 The presence of previous suicide attempts (31.6% versus 20.8%, p<0.001) was 
more frequently reported in the MDE-A group.  
 Patients in the MDE-A group more frequently had a family member requiring 
treatment (32.1% versus 18.8%, p<0.001) or a first degree relative with BD (22.1% 
versus 14.2%, p<0.001) than those in the MDE-N group.  
 
Current psychiatric treatment  
Patients in the MDE-A group were more frequently without any psychiatric treatment 
than those in the MDE-N group (p=0.004) (see Table 1).  
 MDE-A patients were more frequently under treatment with antipsychotics 
(p=0.044), mood stabilizers (p<0.001) or electroconvulsive treatment (ECT) (p<0.001) 
than patients in the MDE-N group. 
 Patients in the MDE-A group were less frequently prescribed with 
antidepressants (ADs) than those in the MDE-N group (<0.001); however, in those 
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taking ADs, an AD-induced hypomania/mania during the current MDE was more 
frequently observed in the MDE-A group than in the MDE-N group (23.1% versus 
15.9%, p<0.001). 
 
Clinical variables associated with aggressiveness 
After performing a stepwise backward multivariate modeling procedure (χ2(8)=300.695, 
p<0.001), the model explained between 10.6% (COX and Snell R Square) and 18.9 % 
(Nagelkerke R Square) of the variance and statistical significance persisted for: age at 
first depressive episode (p<0.001), negatively correlated with aggressiveness; severity 
of mania (p=0.031); diagnosis of BD (p=0.001); comorbidity with BPD (p<0.001) but 
not with substance abuse (p=0.633); absence of current psychiatric treatments 
(p<0.001); presence of psychotic symptoms (p=0.007); marked impairment in 
social/occupational functioning (p=0.002) that were positively correlated with 
aggressiveness. DSM.5-MXS was the variable most significantly associated with 
aggressiveness (p<0.001, OR=3.8) (see Figure 1).  
 In order to control for the possible bias of impulsivity-mediated components 
influencing the association between bipolarity and aggressive behaviors, we performed 
a second stepwise backward multivariate modeling procedure (χ2(8)=275.677, p<0.001), 
excluding the variable of BPD comorbidity. The model explained between 9.7% (COX 
and Snell R Square) and 17.4% (Nagelkerke R Square) of the variance. DSM-5-MXS 
still remained the highest significant association with aggressiveness (p<0.001, 
OR=3.9). Also, the association with BD diagnosis still remained significant (p=0.002, 
OR=1.6) whilst the presence of lifetime suicide attempts became significant at the 
logistic regression (p=0.013, OR=1.4) (see Figure 2). 
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Discussion 
In this multinational sample of 2,811 patients with MDE, a prevalence of aggressive 
behaviors of 14.2% was found. The detected prevalence is slightly higher than that 
found in previous large epidemiological studies (30). 
 Almost one in four BD patients in our study presented physical or verbal 
aggressiveness during a MDE. This is in line with the results of previous findings 
supporting the quite frequent association between aggressiveness and BD (11,30–32). 
 
In general, the presence of aggressiveness during a MDE was associated with a 
higher severity of manic and depressive episodes. This emerged from both 
psychometric and clinical assessment, and included higher rates of psychiatric 
comorbidities, more affective episodes, higher frequencies of lack of psychiatric 
treatment, greater impairment in global social/occupational functioning, more frequent 
psychotic symptoms and higher rates of previous suicide attempts. Similar findings 
were reported in previous studies (13,23,33), showing that the presence of aggressive 
behaviors had a significant impact on the clinical outcome of the BD illness, with major 
implications in terms of management and treatment strategies. 
 Several findings from the present study seem to support that the presence of 
aggressive behaviors in the MDE-A group was associated with bipolarity. First, 
significantly higher frequencies of BD diagnosis were found in depressed patients with 
aggressiveness, whilst a diagnosis of unipolar depression was negatively correlated with 
aggressive behaviors. This is consistent with previous reports of a higher association 
between aggressiveness and BD depression compared to unipolar depression (11). The 
MDE-A group showed higher rates of family history for BD as well as younger age at 
the first depressive episode, which represent the most relevant clinical indicators of 
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unrecognized bipolarity in depressed patients (27,34–36). 
 Interestingly, the presence of mixed features during the current MDE was 
significantly more common in MDE-A patients compared with depressed patients 
without aggressive behaviors. This is in line with current views on the spectrum of 
mixed states (37). Hence, several reports showed that the presence of mixed features 
during a MDE might be considered as a clinical indicator of bipolarity (38–40). The 
higher rates of mixed features in our depressed patients with aggressive behaviors seem 
to further support the inclusion of aggressiveness in the BD rubric and within the pool 
of mixed features during a MDE. This is in accord with the results of a previous study 
which found that the dimension “Feel angry”, as assessed by the Multiple Visual 
Analog Scales of Bipolarity (MVAS-BP) was the second most frequent (49,5%) bipolar 
dimension among the mixed depressive patients (41). 
 As for psychiatric treatment, in the present sample, MDE-A patients had 
lower rates of AD use compared with patients without aggressiveness. Nevertheless, the 
MDE-A patients treated with ADs showed significantly higher rates of AD-induced 
mania/hypomania compared with patients without aggressiveness, which represents 
another strong indicator of bipolarity (20,21,27,34,35,37,42–45). 
 As expected, when considering comorbid psychiatric diagnoses, we found 
that MDE-A patients had higher rates of psychiatric comorbidity, indicating a more 
severe and difficult-to-treat condition. In particular, the comorbidity with BPD and 
substance abuse were significantly more reported in depressed patients with 
aggressiveness. Previous studies found that the presence of comorbid BPD could have 
an independent predictive value in determining trait aggressiveness in patients with BD 
(13). It has been supposed that the link between BD, BPD, substance abuse and 
aggressiveness involves the role of impulsivity (13,46), indicating that aggressive 
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behaviors could be more associated with impulsive-related comorbidities than with 
bipolar illness itself. Nonetheless, in order to control for the possible bias of 
impulsivity-mediated components influencing the association between bipolarity and 
aggressive behaviors, we excluded the variable of BPD comorbidity from the second 
stepwise multivariate modeling procedure (the variable substance abuse yet resulted to 
not be significantly correlated with aggressiveness in the first logistic regression). 
Interestingly, the significance persisted for all the variables considered in the first 
modeling, with DSM-5 mixed features becoming the most significant variable 
associated with aggressiveness.  
 Surprisingly, the presence of lifetime suicide attempts became significant at 
the logistic regression, when BPD comorbidity was excluded in the second model (see 
Figure 2). These results support our hypothesis that aggressiveness could be associated 
with bipolarity per se, independently from comorbid disorders such as BPD and 
substance abuse. 
 The role of aggressiveness in suicidal behaviors has been investigated in 
several studies. Oquendo and colleagues (47) found higher lifetime aggressiveness in 
BD patients with a history of suicide attempts compared with BD non-attempters. The 
same authors (48) reported that aggressive traits besides other clinical factors contribute 
to predict future suicidal behaviors both in depressed BD and MDD individuals. 
Moreover, impulsivity was found to be a reliable predictor of suicide risk in BD and 
MDD patients not as a single trait but only in association with aggressiveness 
(33,49,50). In this context, aggressiveness could be seen as a part of the construct 
associated with suicidal behaviors in depressed BD and MDD patients. Furthermore, in 
our study the presence of DSM-5 mixed features was the variable most significantly 
associated with aggressiveness. Previous studies found that the presence of DSM-5 
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mixed features at the index episode was probably the most important risk factor for 
suicidality (37,51) and partly contributed to the increased risk of suicide observed in 
BD-II compared to unipolar depression (52). 
 Regarding treatment considerations, recent guidelines recommend the need 
for the early detection of aggressive behaviors in mood disorders (53–55). In our 
sample, the MDE-A group presented higher rates of psychotic symptoms and more 
severe mania, together with higher rates of no current pharmacological treatment. 
Furthermore, the MDE-A group showed higher rates of AD-induced hypomania/mania. 
Several reports suggest that a prompt therapeutic strategy should be considered to 
prevent aggressiveness in those patients with higher risk factors, such as severe manic, 
psychotic symptoms and lifetime history of self-aggressive behaviors (56,57). Taken 
together, these results claim for the need of an “anti-aggressive” treatment strategy in 
this subgroup of BD patients. Moreover, AD monotherapy should be avoided and a 
combination treatment with mood stabilizers and/or antipsychotics should be considered 
(58).  
 
The main strengths of the BRIDGE-II-Mix study include the large sample size, and the 
wide range of care settings, both hospital and community, from eight countries across 
three continents. Furthermore, narrow exclusion criteria increase the generalizability of 
the findings. The first limitation is the widely varying rates of hospitalized patients 
across countries, ranging from 1.0% to 57.8%, which reflect economically driven 
policies on the use of hospitalization-based treatment. A second limitation is that the 
participating centers were not randomly selected, which may have led to a bias through 
the inclusion of psychiatrists with a particular interest in bipolar spectrum disorders. 
This may be seen, however, as a positive point, in the sense that some expertise is 
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needed to detect past hypomania in MDE patients. Indeed, in the present study 
aggressiveness in the MDE-A group was assessed retrospectively with high subjectivity 
of the original rating performed by trained psychiatrists (59). This means that the 
definition of aggressiveness relies just on retrospectively coded criteria and selected 
variables already collected in the dataset, rather than ad-hoc variables fetched using 
validated ratings. This may introduce a measurement bias, especially considering that 
the operational definition of aggressiveness adopted is a clinical one.  
Moreover, there is a need for additional correlation analyses regarding the relationship 
between aggressiveness and mixed features, controlling for potential confounders to be 
included in future longitudinal prospective studies using external validators. 
 
In conclusion, aggressiveness might not only be state-related but also a trait component 
of bipolarity and a diagnostic indicator of mixicity in patients with MDE. Moreover, the 
association of aggressiveness and the presence of mixed features in depressed patients 
could represent an indicator of increased risk for suicidal behaviors. Taken together, 
these results might have important implications in terms of the reconsideration of 
aggressiveness for diagnostic criteria for the mixed features specifier. Finally, the 
detection of aggressiveness in MDEs could help in establishing a therapeutic strategy 
aimed at reducing aggressiveness and preventing suicidal tendencies in the perspective 
of a personalized pharmacological treatment for this subtype of patients. 
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